Work

Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.

Year: 2007

Type: article

Source: PubMed

Authors: Zhenmin Ye, Chaoke Tang, Shulin Xu, Bei Zhang, Xueshu Zhang, Terence Moyana, Jicheng Yang, Jim Xiang

Institutions: University of Saskatchewan, Saskatchewan Cancer Agency

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2181409833

FWCI: 0.719

Cites: 53

Cited by: 29

Related to: 10